Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (17731)	1/13/1999 4:41:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

betty, I agree. If next Mondays numbers show a total in the 4,500 to 5,000 level it will establish the following: 1)MUSE is here to stay 2)MUSE has a solid patient base that can grow even without an immediate domestic sales force detailing to PCPs. 3)The Viagra safety issues are now really starting to make patients/doctors consider safer alternatives The new Viagra scripts on Monday was 58,966 which was not much of an increase from the prior week of 56,530. The refills were still strong at 107,625 which is the highest refill rate yet reported. I believe that there are millions of men out there who got prescriptions with multiple refills that will allow the refill numbers to continue to be strong for a given time period but I believe that when many of these patients use up their last Viagra refill, their doctors will be reluctant to just call in a refill. I believe that the new scripts alone demonstrate that the PCPs are no longer so liberal in writing new scripts. The PCPs are now probably taking a more serious look at their Vivagra patient's profiles and if they feel that they are "at risk" they very well may require an office visit with possible additional tests before allowing any refills. Some of these patients will be upset about the restrictive attitude and others will be concerned about the safety risks. Hopefully those concerned about safety will inquire about safer alternatives and/or they will be discussed by their doctors. This will be where MUSE will have the potential to increase new prescriptions even without a sales force. I believe that the next several weeks should tell us a lot about where the safety issues are headed in the doctor's office.